FDA, Trying To Build Trust In Biosimilars, Turns To Generics Strategy
GPhA and other opponents of a California prescriber notification bill say an FDA statement on the standards for interchangeability supports their view; statement’s language that efforts to undermine public confidence in biosimilars are “worrisome” mirrors remarks made by FDA Commissioner Hamburg at a GPhA meeting.
You may also be interested in...
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.